Skip to content

Venture

LOGO 20-01

Technologies

Therapeutic

Indication

Musculoskeletal Disorders

Oncology

Orphan Diseases

Aithera is a revolutionary nanomedicine bone targeted drug delivery controlled release platform technology for the treatment of musculoskeletal conditions focused initially on fracture healing & bone cancer
(osteosarcoma is our first oncology target).

Aithera Team:

Seth Harlem, CEO

Mo Chen, PhD, CSO